The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human Brain
Depression is a common and often recurrent illness with significant negative impact on a global scale. Current antidepressants are ineffective for up to one third of people with depression, many of whom experience persistent symptomatology. 5-HT 4 receptor agonists show promise in both animal models...
Saved in:
Published in | Frontiers in psychiatry Vol. 13; p. 859123 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
12.04.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Depression is a common and often recurrent illness with significant negative impact on a global scale. Current antidepressants are ineffective for up to one third of people with depression, many of whom experience persistent symptomatology. 5-HT
4
receptor agonists show promise in both animal models of depression and cognitive deficit. We therefore studied the effect of the 5-HT
4
partial agonist prucalopride (1 mg daily for 6 days) on the neural processing of emotional faces in 43 healthy participants using a randomised placebo-controlled design. Participants receiving prucalopride were more accurate at identifying the gender of emotional faces. In whole brain analyses, prucalopride was also associated with reduced activation in a network of regions corresponding to the default mode network. However, there was no evidence that prucalopride treatment produced a positive bias in the neural processing of emotional faces. Our study provides further support for a pro-cognitive effect of 5-HT
4
receptor agonism in humans. While our current behavioural and neural investigations do not suggest an antidepressant-like profile of prucalopride in humans, it will be important to study a wider dose range in future studies. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors share last authorship Reviewed by: Philippe De Deurwaerdere, Université de Bordeaux, France; Mohammad Reza Zirak, Mashhad University of Medical Sciences, Iran This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry Edited by: Reza Rahimian, McGill University, Canada |
ISSN: | 1664-0640 1664-0640 |
DOI: | 10.3389/fpsyt.2022.859123 |